BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1242748)

  • 1. Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG.
    Richman SP; Mavligit GM; Wolk R; Gutterman JU; Hersh EM
    JAMA; 1975 Dec; 234(12):1233-5. PubMed ID: 1242748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL; Jessup JM; Cohen MH
    Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with BCG administered by scarification: standardization of reactions and management of side effects.
    Hortobagyi GN; Richman SP; Dandridge K; Gutterman JU; Blumenschein GR; Hersh EM
    Cancer; 1978 Nov; 42(5):2293-303. PubMed ID: 363257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
    Korting HC; Strasser S; Konz B
    Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer.
    Bodurtha A; Kim YH; Laucius JF; Donato RA; Mastrangelo MJ
    Am J Clin Pathol; 1974 Jun; 61(6):747-52. PubMed ID: 4598826
    [No Abstract]   [Full Text] [Related]  

  • 8. Axillary lymphadenopathy: a complication of BCG immunotherapy for melanoma.
    Briggs PC; Heckler FR
    Plast Reconstr Surg; 1988 Jun; 81(6):952-3. PubMed ID: 3375359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter: Malignant melanoma arising de novo within a B.C.G. scarification site.
    Lokich JJ
    Lancet; 1975 Feb; 1(7902):331-2. PubMed ID: 46469
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Unspecific, active BCG vaccination therapy in melanoma using a modified scarification procedure].
    Wolf M; Menzel W; Keller G
    Dermatol Monatsschr; 1978 Apr; 164(4):302-3. PubMed ID: 668966
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and immunologic studies of disseminated BCG infection.
    Rosenberg SA; Seipp C; Sears HF
    Cancer; 1978 May; 41(5):1771-80. PubMed ID: 647627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulomas in melanoma patients treated with BCG immunotherapy.
    Hatzitheofilou C; Obenchain DF; Porter DD; Morton DL
    Cancer; 1982 Jan; 49(1):55-60. PubMed ID: 7053820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 15. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylactic reaction to intralesional B.C.G.
    Proctor JW; Zidar B; Pomerantz M; Yamamura Y; Eng CP; Woodside D
    Lancet; 1978 Jul; 2(8081):162. PubMed ID: 78369
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ; Garnick MB; Legg M
    Oncology; 1979; 36(5):236-41. PubMed ID: 481845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of BCG intralesional therapy: an experience with melanoma.
    Robinson JC
    J Surg Oncol; 1977; 9(6):587-93. PubMed ID: 145518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of the complications occurring in BCG vaccine immunotherapy of patients with malignant neoplasms].
    Grigorovich NA; Risina DIa; Nodel'son SE
    Vopr Onkol; 1984; 30(7):102-6. PubMed ID: 6464396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.